Article Sidebar

PDF (Tiếng Việt)
Published: 2025-07-28
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v192i7.3659
Issue
Vol. 192 No. 7 (2025)
Section
Các bài báo
How to Cite
Chỉnh, N. V., Hương, T. T. T., & Kiệt, P. H. T. (2025). 58. Direct medical costs of treatment regimens for EGFR-mutant non-small cell lung cancer in Vietnam. Journal of Medical Research, 192(7), 558-567. https://doi.org/10.52852/tcncyh.v192i7.3659

58. Direct medical costs of treatment regimens for EGFR-mutant non-small cell lung cancer in Vietnam

Nguyen Van Chinh, Tran Thi Thanh Huong, Pham Huy Tuan Kiet

Main Article Content

Abstract

A retrospective study was conducted using the Vietnam Social Security database to estimate the direct medical costs (DMC) of treatment regimens for non-small cell lung cancer (NSCLC) with EGFR mutations in 2020. A multivariate linear regression model was used to identify factors associated with the total DMC of NSCLC patients. The average total DMC per year for NSCLC patients was 113.9 million VND per person; 84.30% of the total cost went towards chemotherapy. The TKI treatment regimen had a lower average DMC per year compared to pre-TKI chemotherapy and post-TKI chemotherapy (110.9 million VND vs. 113.8 million VND and 128.1 million VND per person, p < 0.001). Factors such as the number of inpatient days, treatment regimen, health insurance coverage rate, and economic status were found to be associated with the total DMC (p < 0.05). Therefore, selecting cost-effective TKI drugs to reduce the economic burden on patients with NSCLC is crucial.

Article Details

Keywords

Non-small cell lung cancer, direct cost, direct medical cost, Vietnam Social Security

References

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263. doi:10.3322/caac.21834.
2. Yousefi M, Jalilian H, Heydari S, et al. Cost of Lung Cancer: A Systematic Review. Value Health Reg Issues. 2023; 33: 17-26. doi:10.1016/j.vhri.2022.07.007.
3. Fan S, Mao Z, Lee AH, et al. Economic costs of lung cancer in China. Int J Oncol Res. 2017; 2(1): 1-7. doi:10.23937/ijor-2017/1710007.
4. Duma N, Santana-Davila R, Molina JR. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019; 94(8): 1623-1640. doi:10.1016/j.mayocp.2019.01.013.
5. Ha TV, Hoang MV, Vu MQ, et al. Willingness to pay for a quality-adjusted life year among advanced non-small cell lung cancer patients in Viet Nam, 2018. Medicine (Baltimore). 2020; 99(9): e19379. doi:10.1097/MD.0000000000019379.
6. Bộ Y tế. Quyết định số 4825/QĐ-BYT năm 2018 về việc ban hành tài liệu chuyên môn “Hướng dẫn chẩn đoán và điều trị ung thư phổi không tế bào nhỏ.” Hà Nội: Bộ Y tế; 2018.
7. Hoang VM, Pham CP, Vu QM, et al. Household Financial Burden and Poverty Impacts of Cancer Treatment in Vietnam. BioMed Res Int. 2017; 2017: 9350147. doi:10.1155/2017/9350147.
8. Kernick D. Costing interventions in primary care. Fam Pract. 2000; 17(1): 66-70. doi:10.1093/fampra/17.1.66.
9. Tổng cục Thống kê. Kết quả Khảo sát mức sống dân cư Việt Nam năm 2020. Hà Nội: Nhà xuất bản Thống kê; 2021.
10. Verleger K, Penrod JR, Manley Daumont M, et al. Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe. Clin Outcomes Res CEOR. 2020; 12: 23-33. doi:10.2147/CEOR.S223760.
11. Migliorino MR, Santo A, Romano G, et al. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. J Cancer Res Clin Oncol. 2017; 143(5): 783-791. doi:10.1007/s00432-016-2326-x.
12. De Barros Reis C, Knust RE, De Aguiar Pereira CC, et al. Factors associated with non-small cell lung cancer treatment costs in a Brazilian public hospital. BMC Health Serv Res. 2018; 18(1): 124. doi:10.1186/s12913-018-2933-0.
13. Nipp RD, Kirchhoff AC, Fair D, et al. Financial Burden in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2017; 35(30): 3474-3481. doi:10.1200/JCO.2016.71.7066.
14. Limwattananon C, Limwattananon S, Waleekhachonloet O, et al. Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand. Lung Cancer Amst Neth. 2018; 120: 91-97. doi:10.1016/j.lungcan.2018.04.003.
15. Gu X, Zhang Q, Chu YB, et al. 6. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lung Cancer Amst Neth. 2019; 127: 84-89. doi:10.1016/j.lungcan.2018.11.029.